Lipocine (LPCN) Announces Launch of Public Offering of Common Stock, Warrants

Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced the launch of a public offering of units consisting of shares of its common stock (or pre-funded warrants) and warrants to purchase its common stock. The shares of common stock (or pre-funded warrants) and warrants comprising the units are immediately separable and will be issued separately, but will be purchased together. The offering is being conducted on a best-efforts basis and is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.

Roth Capital Partners is acting as sole agent for the public offering.

The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-220942) (including a prospectus) previously filed with and declared effective by the U.S. Securities and Exchange Commission (the "SEC").

You May Also Be Interested In

• Yarrow Bioscience prices $150M public offering at $26 per share
• Vertical Data agrees to buy 4.5 MW Sweden data center site
• Allarity Therapeutics files SPAC registration for $100M IPO